August 13, 2018 10:00 AM EDTUpdated 10:44 AM
Bioregnum
Opinion

Ver­tex’s fight club rule: Block new treat­ments to cys­tic fi­bro­sis pa­tients un­til Orkam­bi is re­im­bursed prop­er­ly

The bare-knuck­le brawl be­tween Ver­tex’s ex­ec­u­tive crew and NICE has now ex­tend­ed to its new cys­tic fi­bro­sis com­bo Symke­vi — match­ing teza­caftor and iva­caftor. …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

FDA pos­es ef­fi­ca­cy, safe­ty ques­tions over four can­cer drugs ahead of two-day ad­comm

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

HHS can re­quire ap­proval for drug­mak­ers to ap­ply 340B re­bate mod­els, court rules

No­vo Nordisk’s glob­al obe­si­ty leader is mov­ing on; Flag­ship biotech gets CEO from Schol­ar Rock

A service from the Financial Times